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A 70-year-old woman presented with an 18-month history of recurrent episodes of dizziness, 
alleviated by sugary drinks. During one of these episodes, a low blood glucose of 1.6 mmol/l 
was noted. Past medical history included atrial fibrillation and severe chronic obstructive 
pulmonary disease (COPD), necessitating long-term oxygen therapy. Given the high index of 
suspicion of spontaneous hypoglycaemia, further Investigations commenced with a 
supervised 72-hour fast which confirmed symptomatic hyperinsulinaemic hypoglycaemia 
(serum glucose of 1.8mmol/l (NR 3-7.8), insulin 17.3 milliunits/L, C-peptide 2418 pmol/L) at 
34 hours. Serum sulphonylurea screen was negative. CT revealed a 18mm enhancing lesion 
in the uncinate consistent with a neuroendocrine tumour that was confirmed by endoscopic 
ultrasound with fine needle aspiration (EUS-FNA) [Figure 1]. The patient was prescribed 
diazoxide 50mg, but this discontinued due to acute fluid retention. She remained 
symptomatic but was a poor surgical candidate so was commenced on a low glycaemic 
index diet and octreotide. This was unsuccessful and she remained on a continuous infusion 
of 10% dextrose. The patient was therefore referred for EUS guided radiofrequency ablation 
(RFA). 
RFA causes thermal coagulative necrosis through the administration of a high-frequency 
current. The technique is now part of standard therapy for several tumours including 
hepatocellular carcinoma.1 Recently a new monopolar RFA probe has been developed that 
can be placed down the working channel of a linear echoendoscope, enabling RFA to be 
administered under EUS-guidance (Habib EUS-RFA catheter, Emcision Ltd, London). To 
date it has been used in the management of two neuroendocrine tumours worldwide and in 
both cases the tumour decreased in size.2  
EUS-guided RFA was undertaken as a series of three treatments, each one week apart 
[Table 1]. The procedures were performed under deep propofol sedation or General 
Anaesthesia. During the first procedure, 3 applications were administered at 10W and 
directed into the central part of the tumour [Figure 3]. After the procedure glucose 
requirements initially decreased but increased back to pre-treatment levels within 24 hours. 
A Day 1 post-treatment CT showed no complications and some central necrosis within the 
tumour [Figure 3]. During the second treatment the probe was placed within the tumour in 
two different planes and 8 sequential treatments were administered at 10W. Glucose 
requirements immediately halved and repeat imaging showed a larger area of central 
necrosis but the edge of the tumour was unchanged. On the third occasion 14 sequential 
treatments were administered. After 10 treatments in 3 planes, a contrast-harmonic EUS 
with SonoVue (sulfur hexafluoride microbubbles; Bracco UL Ltd) was performed and 
revealed remaining tumour within the distal wall so 4 further RFA treatments were directed at 
this area. After the final EUS-RFA treatment glucose requirements ceased and octreotide 
therapy was withdrawn [Table 1]. Before discharge, a 72-hour supervised fast was 
completed without hypoglycaemia consistent with biochemical remission. Post-procedural 
CT showed that the lesion had been almost completely replaced by necrotic tissue and 
Gallium 68 Dotatate PET-CT scan showed that the abnormal uptake within the uncinate 
process had resolved. The patient was discharged home and remained well and 
asymptomatic after ten months. This case supports the use of EUS-RFA in the management 
of patients with functional PNETs who have failed multiple medical therapies and cannot 
undergo surgery due to co-morbidities. Long-term outcomes and further experience is 
required but this novel approach should be considered for selected cases.                                                                                                                                                                                                       
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Figure 1:  
a. Pre-treatment CT showing a 18mm round lesion with arterial enhancement, characteristic 
of a PNET          
b. Pre-treatment MRI                                                  
c: Pre-treatment EUS showing a hypoechoic circular lesion 
 
Figure 2:  
a. EUS image of a 19G FNA needle at the edge of the insulinoma and the Habib EUS-
RFA probe advanced across the length of the lesion  
b. Fluoroscopic image of the Habib EUS-RFA probe within the insulinoma 
Figure 3: 
a. Pre-treatment CT - 18mm round arterial enhancing lesion 
b. Post 1st EUS-RFA treatment - area of central low density necrosis 
c. Post-final EUS-RFA treatment - larger area of central low density necrosis 
 
 
Table 1. Treatment summary table  
 Number 
of 
ablations 
Individual 
ablation 
Time (s) 
Procedure time - 
first ablation to 
last (mins) 
10% Dextose  
requirements 
(ml/Hr)  
Tumour 
volume 
(cm3) 
1st  EUS-RFA 
Treatment 
3 120  6  100 
(Pre-treatment) 
2.14 
2nd  EUS-RFA 
Treatment 
8 90  33  15 
(Post-treatment) 
0.52 
3rd  EUS-RFA 
Treatment 
14 90  55  0 
(Post-treatment) 
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